...
search icon
ebs-img

Emergent Biosolutions Inc, Common Stock

EBS

NYQ

$11.02

-$0.17

(-1.52%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$597.11M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
699.53K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.57
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.42 L
$15.1 H
$11.02

About Emergent Biosolutions Inc, Common Stock

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameEBSSectorS&P500
1-Week Return7.83%3.54%-0.58%
1-Month Return19.14%7.51%1.89%
3-Month Return13.96%-0.85%3.24%
6-Month Return-25.39%-1.67%10.09%
1-Year Return502.19%5.2%22.09%
3-Year Return-75.67%13.08%35.68%
5-Year Return-80.23%44.4%83.47%
10-Year Return-59.46%111.45%200.41%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue1.11B1.56B1.79B1.12B1.05B[{"date":"2019-12-31","value":61.69,"profit":true},{"date":"2020-12-31","value":86.76,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":62.53,"profit":true},{"date":"2023-12-31","value":58.53,"profit":true}]
Cost of Revenue433.50M524.00M757.50M693.70M705.40M[{"date":"2019-12-31","value":57.23,"profit":true},{"date":"2020-12-31","value":69.17,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.58,"profit":true},{"date":"2023-12-31","value":93.12,"profit":true}]
Gross Profit672.50M1.03B1.04B427.20M343.90M[{"date":"2019-12-31","value":64.96,"profit":true},{"date":"2020-12-31","value":99.63,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":41.27,"profit":true},{"date":"2023-12-31","value":33.22,"profit":true}]
Gross Margin60.80%66.31%57.75%38.11%32.77%[{"date":"2019-12-31","value":91.7,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":87.08,"profit":true},{"date":"2022-12-31","value":57.48,"profit":true},{"date":"2023-12-31","value":49.43,"profit":true}]
Operating Expenses558.40M597.60M640.90M593.20M1.04B[{"date":"2019-12-31","value":53.49,"profit":true},{"date":"2020-12-31","value":57.24,"profit":true},{"date":"2021-12-31","value":61.39,"profit":true},{"date":"2022-12-31","value":56.82,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income114.10M433.80M352.60M(166.00M)(726.40M)[{"date":"2019-12-31","value":26.3,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":81.28,"profit":true},{"date":"2022-12-31","value":-38.27,"profit":false},{"date":"2023-12-31","value":-167.45,"profit":false}]
Total Non-Operating Income/Expense(75.10M)(57.90M)(72.70M)(93.00M)(83.80M)[{"date":"2019-12-31","value":-7510000000,"profit":false},{"date":"2020-12-31","value":-5790000000,"profit":false},{"date":"2021-12-31","value":-7270000000,"profit":false},{"date":"2022-12-31","value":-9300000000,"profit":false},{"date":"2023-12-31","value":-8380000000,"profit":false}]
Pre-Tax Income77.40M407.20M314.40M(221.70M)(731.20M)[{"date":"2019-12-31","value":19.01,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":77.21,"profit":true},{"date":"2022-12-31","value":-54.44,"profit":false},{"date":"2023-12-31","value":-179.57,"profit":false}]
Income Taxes22.90M102.10M83.50M2.10M29.30M[{"date":"2019-12-31","value":22.43,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":81.78,"profit":true},{"date":"2022-12-31","value":2.06,"profit":true},{"date":"2023-12-31","value":28.7,"profit":true}]
Income After Taxes54.50M305.10M230.90M(223.80M)(760.50M)[{"date":"2019-12-31","value":17.86,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":75.68,"profit":true},{"date":"2022-12-31","value":-73.35,"profit":false},{"date":"2023-12-31","value":-249.26,"profit":false}]
Income From Continuous Operations100.30M305.10M230.90M(223.80M)(790.20M)[{"date":"2019-12-31","value":32.87,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":75.68,"profit":true},{"date":"2022-12-31","value":-73.35,"profit":false},{"date":"2023-12-31","value":-259,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income54.50M305.80M219.50M(223.80M)(760.50M)[{"date":"2019-12-31","value":17.82,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":71.78,"profit":true},{"date":"2022-12-31","value":-73.19,"profit":false},{"date":"2023-12-31","value":-248.69,"profit":false}]
EPS (Diluted)2.777.856.00(2.26)(5.54)[{"date":"2019-12-31","value":35.29,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":76.43,"profit":true},{"date":"2022-12-31","value":-28.79,"profit":false},{"date":"2023-12-31","value":-70.57,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

EBS
Cash Ratio 0.65
Current Ratio 2.88
Quick Ratio 1.47

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

EBS
ROA (LTM) -4.22%
ROE (LTM) -34.64%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

EBS
Debt Ratio Lower is generally better. Negative is bad. 0.66
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.34

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

EBS
Trailing PE NM
Forward PE 6.82
P/S (TTM) 0.53
P/B 1.19
Price/FCF 4
EV/R 1.02
EV/Ebitda 54.59
PEG 1.55

FAQs

What is Emergent Biosolutions Inc share price today?

Emergent Biosolutions Inc (EBS) share price today is $11.02

Can Indians buy Emergent Biosolutions Inc shares?

Yes, Indians can buy shares of Emergent Biosolutions Inc (EBS) on Vested. To buy Emergent Biosolutions Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in EBS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Emergent Biosolutions Inc be purchased?

Yes, you can purchase fractional shares of Emergent Biosolutions Inc (EBS) via the Vested app. You can start investing in Emergent Biosolutions Inc (EBS) with a minimum investment of $1.

How to invest in Emergent Biosolutions Inc shares from India?

You can invest in shares of Emergent Biosolutions Inc (EBS) via Vested in three simple steps:

  • Click on Sign Up or Invest in EBS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Emergent Biosolutions Inc shares
What is Emergent Biosolutions Inc 52-week high and low stock price?

The 52-week high price of Emergent Biosolutions Inc (EBS) is $15.1. The 52-week low price of Emergent Biosolutions Inc (EBS) is $1.42.

What is Emergent Biosolutions Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Emergent Biosolutions Inc (EBS) is 1.19

What is the Market Cap of Emergent Biosolutions Inc?

The market capitalization of Emergent Biosolutions Inc (EBS) is $597.11M

What is Emergent Biosolutions Inc’s stock symbol?

The stock symbol (or ticker) of Emergent Biosolutions Inc is EBS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top